Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review

doi:10.3748/wjg.v31.i37.111435

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 37

This Article

(53)

(48)

(0)

(7)

(3917)

(8)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 7, 2025; 31(37): 111435
Published online Oct 7, 2025. doi: 10.3748/wjg.v31.i37.111435

Full Size Figure Download Figure

Figure 1 Mechanisms of obesity and liver disease. Insulin resistance leads to elevated free fatty acids, hepatic lipid accumulation, oxidative stress, and inflammation. These processes activate hepatic stellate cells and promote liver fibrosis. Image adapted from Servier Medical ART (https://smart.servier.com/), licensed under CC BY 4.0 (https://creativecommons.org/Licenses/by/4.0/). Glu: Glucose; FFA: Free fatty acids; IL: Interleukin; TNF: Tumor necrosis factor.

Citation: Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, Concepción-Urteaga LA, Pérez-Reyes AI, Quiroz-Aldave JE, Paz-Ibarra J. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. World J Gastroenterol 2025; 31(37): 111435
URL: https://www.wjgnet.com/1007-9327/full/v31/i37/111435.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i37.111435

Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, Concepción-Urteaga LA, Pérez-Reyes AI, Quiroz-Aldave JE, Paz-Ibarra J. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. World J Gastroenterol 2025; 31(37): 111435 [PMID: 41025003 DOI: 10.3748/wjg.v31.i37.111435]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.